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a b s t r a c t
The antibacterial and antifungal activity of a series of products, in which the 1,5-dimethyl-4-(cyano-
NNO-azoxy)pyrazol-3-yl and 1,3-dimethyl-4-(cyano-NNO-azoxy)pyrazol-5-yl moieties were linked to
pyridine, pyrazole, isoxazole, thiophene and the furan ring, were examined. No molecule displayed activ-
ity against the Gram-negative bacteria tested. Conversely, some compounds displayed activity against
two Staphylococcus aureus strains, including the methicillin resistant strain. All compounds displayed
interesting antifungal activity, the most active compound of the series being the thiophene derivative
7a. This compound’s activity against Candida krusei and Candida glabrata (MIC = 0.25 and 0.5 lg/mL,
respectively), two fungal species resistant to azoles, is noteworthy. The presence of the cyano function
appeared essential for activity.
 2011 Elsevier Ltd. All rights reserved.
The azoxycyanide functional group (–N(O)@N–CN) was
originally discovered in the antibiotic calvatic acid (4-carboxy-
phenyl-ONNazoxycyanide, 4-(cyano-NNO-azoxy)benzoic acid),
which was ﬁrst isolated from a culture broth of Calvatia lilacina
(BERK.) Henn. P.,1 then from cultures of Calvatia craniformis
(SHW.) Fr.,2 and Lycoperdon pyriforme.3
O
OH
N+
O-
N CN
Calvatic acid
Calvatic acid displays signiﬁcant antifungal and antibacterial
activity, as well as in vitro and in vivo antitumor activity.2,4 It also
has activity against a number of strains of Helicobacter pylori,
including metronidazole resistent ones.5 The antibiotic also shows
a range of speciﬁc biological functions; among these are inhibition
of [3H] colchicine binding to soluble tubulin, inhibition of human
placenta glutathione transferase, as well as of ornithine decarboxyl-
ase.6–8 The structure of Calvatic acid has been used as a starting
point in several other studies; in particular, the azoxycyanide func-
tion has been inserted in a variety of aryl and heteroaryl vectors.9–13
The resulting compounds displayed the general activities of the
lead, but with a range of potency and speciﬁcity. They are superior
antifungal agents compared to the parent compound. These deriv-
atives have also been examined as potential agricultural fungi-
cides.14 The results are reported of a study of the antibacterial
and antifungal activity of a series of products in which the
1,5-dimethyl-4-(cyano-NNO-azoxy)pyrazol-3-yl and 1,3-di-
methyl-4-(cyano-NNO-azoxy)pyrazol-5-yl moieties R3 and R5 (Ta-
ble 1) were linked to pyridine, pyrazole, isoxazole, thiophene and
furan ring. In order to elucidate the signiﬁcance of the cyano func-
tion on activity, the carbamoyl 10 and tosyl 11 analogues of 7a, the
most active compound of the series, were also examined.
Scheme 1 outlines the preparation of the ﬁnal azoxycyano
derivatives. The starting materials were the 1-methyl-4-nitrosopy-
razoles derivatives 1–9, bearing methyl and heteroaryl substitu-
ents at 3- and 5- positions. These products were transformed
into the ﬁnal compounds by regiospeciﬁc synthesis, as described
by Fruttero et al.15 and later modiﬁed by Wood et al,13 with the
exception of the oxidative-breakdown-susceptible furan derivative
9a, for which the procedure was partially modiﬁed. Nitrosoderiva-
tives were treated in dry CH2Cl2 with a mixture of cyanamide
(NH2CN) and (diacetoxy)iodobenzene (IBA), giving the expected ﬁ-
nal products, probably through the intermediate formation of
cyanonitrene. All products showed the fragment ions [M40]+in
their mass spectra, due to loss of CN2, typical of this class of com-
pounds.16 Compound 10 was easily obtained by bubbling HCl
through a THF/H2O solution of 7a, following the general procedure
described elsewhere,12 while compound 11was synthesized by ac-
tion of the nitrene precursor N-tosyliminoiodinane, prepared by a
known procedure,17 on 7 dissolved in acetonitrile containing acti-
vated 4 Å molecular sieves (MS) and CuCl (Scheme 2).
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The ﬁrst seven products were tested against two strains of
Staphylococcus aureus, one resistant (MR) and the other susceptible
(MS) to methicillin, three species of Gram-negative bacteria, Pro-
teus mirabilis, Escherichia coli and Pseudomonas aeruginosa, six fun-
gal species belonging to Candida spp., and Cryptococcus neoformans
var. neoformans. Because both yeasts and S. aureus can be normal
microbiota of human mucosa and skin, the yeasts and the two S.
aureus isolates used in this study were collected from human ster-
ile clinical specimens (blood and cerebrospinal ﬂuid), Gram-nega-
tive bacteria were isolated from urine having a colony forming unit
(CFU) count above the cutoff of >105 CFU. Antimicrobial assays
were performed with a microdilution broth method, following
standard protocols for in vitro antibacterial and antifungal suscep-
tibility testing.21,22 The results are in Table 123.
The antimicrobial data showed that none of the molecules dis-
played activity against the Gram negative bacteria tested. Con-
versely, except for 1a and 6a, they displayed some activity
against both S. aureus strains, including the MR strain, against
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Scheme 2. Reagents and conditions: (a) HCl gas, THF/H2O, 0 C. (b) N-tos-
yliminoiodinane, CuCl, 4 Å MS, dry acetonitrile, rt.
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Scheme 1. Reagents and conditions: (a) NH2CNNH2CN, (diacetoxy)iodobenzene
(IBA), dry CH2Cl2, 30 C.
Table 2
Comparison of in vitro activities of the designed compounds with that of the widely used systemic antifungal drugs (MIC, lg/mL)
Species 7a 8a 9a Fluconazole Voriconazole Posaconazole Amphotericinb
S
R3 S
R5
O
R3
C. albicans 31 1 4 2 0.25 <0.008 0.008 0.5
C. albicans 41 0.5 ND ND 0.12 <0.008 0.016 0.5
C. albicans 47 1 4 4 0.25 0.008 0.016 1
C. albicans 48 1 4 4 0.12 <0.008 0.008 0.5
C. krusei 31 0.5 1 1 32 0.12 0.25 0.5
C. krusei 43 1 1 2 64 0.5 0.5 1
C. krusei 48 0.5 2 2 32 0.25 0.25 1
C. tropicalis 33 8 32 128 1 <0.008 0.12 1
C. tropicalis 11 8 32 32 1 0.12 0.12 1
C. tropicalis 15 ND 64 128 1 0.06 0.25 1
C. tropicalis 22 16 32 128 2 0.06 0.25 0.5
C. glabrata 30 0.25 2 1 8 0.25 0.5 1
C. glabrata 32 0.25 2 2 >256 4 >8 0.5
C. glabrata 46 0.25 2 1 16 0.25 1 1
C. glabrata 49 0.25 2 1 8 0.12 0.25 0.5
C. parapsilosis 26 8 16 8 1 <0.008 0.03 0.5
C. parapsilosis 39 ND 16 16 1 0.016 0.06 0.5
C. parapsilosis 44 8 ND ND 2 0.016 0.03 0.5
C. parapsilosis 19 16 32 64 1 0.008 0.03 0.5
Cr. neoformans 14 2 0.25 0.25 0.5 <0.008 0.03 0.25
Cr. neoformans 27 2 0.25 0.25 2 0.016 0.06 0.12
Cr. neoformans 30 2 0.5 0.25 4 0.016 0.12 0.5
Cr. neoformans 25 2 0.5 0.25 2 0.016 0.06 0.5
C. albicans ATCC ND 4 1 0.12 0.008 0.008 0.5
C. krusei ATCC 0.5 1 1 32 0.25 0.25 1
C. parapsilosis ATCC 16 32 32 2 0.06 0.12 1
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which erythromycin and ciproﬂoxacin are also inactive, as deter-
mined following the established clinical breakpoint P1 lg/mL.
From this standpoint, the lowest MIC values were displayed by
derivatives 4a, 5a, and 7a, respectively bearing the 3-methyl-5-
oxazolyl, 5-methyl-3-oxazolyl, and thiophen-2-yl substituent at
the 3-position of the pyrazolylazoxycyanide scaffold R3. As far as
antifungal activity is concerned, the most active product was 7a:
this is a potent antifungal product active against almost all the spe-
cies tested. Candida parapsilosis and Candida tropicalis isolates had
higher MIC values than those of the other yeasts tested. The activ-
ity against Candida krusei, which displays intrinsic ﬂuconazole
resistance, and against Candida glabrata, which has acquired resis-
tance to azoles, are of note (Table 2).24 When the thienyl substitu-
ent was moved to position 5 of the pyrazole ring, to give compound
8a, the level of activity remained high, MIC values being within
±2 log2 dilutions. Compound 8a was particularly active against
the strains of Cryptococcus neoformans, which was susceptible to
all the pyrazolylazoxycyanide derivatives tested. When in 7a the
furan moiety was substituted for the thiophene, giving compound
9a, activity against all the species under study remained high,
declining only for the strains of C. tropicalis. The presence of the
azoxycyano function in these products appeared to be essential
to their activity: the cyano group was substituted in 7a with two
other electron-withdrawing moieties, the carbamoyl and the tosyl
moiety respectively, giving products 10 and 11, which were
inactive.
In conclusion, interesting pyrazole derivatives displaying anti-
fungal activity were developed. In particular, compounds 7a, 8a,
9a deserve further structural modulation, owing to their potent ac-
tion against C. krusei and C. glabrata, two fungal species resistant to
azoles.
Supplementary data
Supplementary data (synthesis of intermediates 7, 8, full exper-
imental procedures, physicochemical characterization, and ele-
mental analyses for the compounds described, is available free of
charge via the Internet at http://) associated with this article can
be found, in the online version, at doi:10.1016/j.bmcl.2011.03.101.
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included: C. krusei ATCC 6258, C. parapsilosis ATCC 22019, Candida albicans
ATCC 90028. Antibacterial susceptibility was tested as for yeasts, with a
microdilution broth method using 96-well microtiter plates; Mueller Hinton
broth was used instead of RPMI 1640 as medium. After overnight growth on
Mueller Hinton broth at 35 C, each bacterial isolate was diluted to achieve a
suspension of approximately 1–5  108 CFU/mL. Aliquots (0.1 mL) of the latter
dilution was then placed in 11 wells of a single row and incubated at 35 C.
Reading was after 24 h of incubation, and the lowest concentration that had
inhibited visible growth was recorded as the MIC.
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